Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder

Naga Venkatesha Murthy, Rengyi Xu, Wei Zhong, Philip D. Harvey

Research output: Contribution to journalArticle

Abstract

Background: Patients with major depressive disorder (MDD) show impairments in cognitive functioning, including deficits on performance-based measures of functional capacity. A proportion of patients with MDD may achieve higher scores at baseline, and may not show a detectable response to treatment. How to identify these cases is the goal of this investigation. Methods: Retrospective analyses of data from the CONNECT study with vortioxetine were performed to determine whether the Work Limitations Questionnaire (WLQ) can be used to exclude very high-performing patients on the functional capacity outcome measure, University of California San Diego Performance-Based Skills Assessment (UPSA), in studies evaluating cognitive function impairment in MDD, to identify those with greater potential for treatment response. The post-hoc analyses included data on cognitive function assessed with a Digit Symbol Substitution Test (DSST) from vortioxetine-treated patients. Results: WLQ score >13 identified patients with greater impairments in UPSA-Brief (UPSA-B). Patients with WLQ scores >13, but not with scores ≤13, showed statistically significant improvements with vortioxetine treatment in UPSA-B and DSST compared with placebo. Limitations: Study limitations include small sample size and use of post-hoc analyses. The generalizability of this analysis is limited to working patients with MDD. Conclusions: The WLQ can be used to identify patients with MDD with high potential for treatment response in studies evaluating cognitive function impairment while excluding patients likely to achieve ceiling scores on UPSA. This approach helps identify higher performers on potential outcomes measures without biasing the study by requiring a specific UPSA cutoff score for eligible participants.

Original languageEnglish (US)
Pages (from-to)550-556
Number of pages7
JournalJournal of Affective Disorders
Volume260
DOIs
StatePublished - Jan 1 2020

Fingerprint

Major Depressive Disorder
Cognition
Outcome Assessment (Health Care)
Cognitive Dysfunction
vortioxetine
Therapeutics
Sample Size
Placebos
Surveys and Questionnaires

Keywords

  • Cognitive impairment
  • Employment
  • Functioning
  • Major depressive disorder
  • Vortioxetine

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder. / Murthy, Naga Venkatesha; Xu, Rengyi; Zhong, Wei; Harvey, Philip D.

In: Journal of Affective Disorders, Vol. 260, 01.01.2020, p. 550-556.

Research output: Contribution to journalArticle

@article{de1d5391ea8a46c78ba97c9ceb947e1a,
title = "Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder",
abstract = "Background: Patients with major depressive disorder (MDD) show impairments in cognitive functioning, including deficits on performance-based measures of functional capacity. A proportion of patients with MDD may achieve higher scores at baseline, and may not show a detectable response to treatment. How to identify these cases is the goal of this investigation. Methods: Retrospective analyses of data from the CONNECT study with vortioxetine were performed to determine whether the Work Limitations Questionnaire (WLQ) can be used to exclude very high-performing patients on the functional capacity outcome measure, University of California San Diego Performance-Based Skills Assessment (UPSA), in studies evaluating cognitive function impairment in MDD, to identify those with greater potential for treatment response. The post-hoc analyses included data on cognitive function assessed with a Digit Symbol Substitution Test (DSST) from vortioxetine-treated patients. Results: WLQ score >13 identified patients with greater impairments in UPSA-Brief (UPSA-B). Patients with WLQ scores >13, but not with scores ≤13, showed statistically significant improvements with vortioxetine treatment in UPSA-B and DSST compared with placebo. Limitations: Study limitations include small sample size and use of post-hoc analyses. The generalizability of this analysis is limited to working patients with MDD. Conclusions: The WLQ can be used to identify patients with MDD with high potential for treatment response in studies evaluating cognitive function impairment while excluding patients likely to achieve ceiling scores on UPSA. This approach helps identify higher performers on potential outcomes measures without biasing the study by requiring a specific UPSA cutoff score for eligible participants.",
keywords = "Cognitive impairment, Employment, Functioning, Major depressive disorder, Vortioxetine",
author = "Murthy, {Naga Venkatesha} and Rengyi Xu and Wei Zhong and Harvey, {Philip D.}",
year = "2020",
month = "1",
day = "1",
doi = "10.1016/j.jad.2019.09.025",
language = "English (US)",
volume = "260",
pages = "550--556",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder

AU - Murthy, Naga Venkatesha

AU - Xu, Rengyi

AU - Zhong, Wei

AU - Harvey, Philip D.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Background: Patients with major depressive disorder (MDD) show impairments in cognitive functioning, including deficits on performance-based measures of functional capacity. A proportion of patients with MDD may achieve higher scores at baseline, and may not show a detectable response to treatment. How to identify these cases is the goal of this investigation. Methods: Retrospective analyses of data from the CONNECT study with vortioxetine were performed to determine whether the Work Limitations Questionnaire (WLQ) can be used to exclude very high-performing patients on the functional capacity outcome measure, University of California San Diego Performance-Based Skills Assessment (UPSA), in studies evaluating cognitive function impairment in MDD, to identify those with greater potential for treatment response. The post-hoc analyses included data on cognitive function assessed with a Digit Symbol Substitution Test (DSST) from vortioxetine-treated patients. Results: WLQ score >13 identified patients with greater impairments in UPSA-Brief (UPSA-B). Patients with WLQ scores >13, but not with scores ≤13, showed statistically significant improvements with vortioxetine treatment in UPSA-B and DSST compared with placebo. Limitations: Study limitations include small sample size and use of post-hoc analyses. The generalizability of this analysis is limited to working patients with MDD. Conclusions: The WLQ can be used to identify patients with MDD with high potential for treatment response in studies evaluating cognitive function impairment while excluding patients likely to achieve ceiling scores on UPSA. This approach helps identify higher performers on potential outcomes measures without biasing the study by requiring a specific UPSA cutoff score for eligible participants.

AB - Background: Patients with major depressive disorder (MDD) show impairments in cognitive functioning, including deficits on performance-based measures of functional capacity. A proportion of patients with MDD may achieve higher scores at baseline, and may not show a detectable response to treatment. How to identify these cases is the goal of this investigation. Methods: Retrospective analyses of data from the CONNECT study with vortioxetine were performed to determine whether the Work Limitations Questionnaire (WLQ) can be used to exclude very high-performing patients on the functional capacity outcome measure, University of California San Diego Performance-Based Skills Assessment (UPSA), in studies evaluating cognitive function impairment in MDD, to identify those with greater potential for treatment response. The post-hoc analyses included data on cognitive function assessed with a Digit Symbol Substitution Test (DSST) from vortioxetine-treated patients. Results: WLQ score >13 identified patients with greater impairments in UPSA-Brief (UPSA-B). Patients with WLQ scores >13, but not with scores ≤13, showed statistically significant improvements with vortioxetine treatment in UPSA-B and DSST compared with placebo. Limitations: Study limitations include small sample size and use of post-hoc analyses. The generalizability of this analysis is limited to working patients with MDD. Conclusions: The WLQ can be used to identify patients with MDD with high potential for treatment response in studies evaluating cognitive function impairment while excluding patients likely to achieve ceiling scores on UPSA. This approach helps identify higher performers on potential outcomes measures without biasing the study by requiring a specific UPSA cutoff score for eligible participants.

KW - Cognitive impairment

KW - Employment

KW - Functioning

KW - Major depressive disorder

KW - Vortioxetine

UR - http://www.scopus.com/inward/record.url?scp=85072243157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072243157&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2019.09.025

DO - 10.1016/j.jad.2019.09.025

M3 - Article

C2 - 31539692

AN - SCOPUS:85072243157

VL - 260

SP - 550

EP - 556

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -